Mark Ragosa, the Chief Financial Officer of Kiniksa Pharmaceuticals (NASDAQ:KNSA) International, plc (NASDAQ:KNSA), recently sold company shares totaling approximately $593,997. The transactions, conducted on December 6 and December 9, involved sales of Class A Ordinary Shares at prices ranging from $21.27 to $21.38. The sales occurred as the stock trades near its current price of $21.37, with the company showing strong revenue growth of 54% over the last twelve months. According to InvestingPro analysis, KNSA currently trades close to its Fair Value.
In addition to the sales, Ragosa executed options to acquire shares at prices between $10.76 and $11.10, amounting to a total acquisition value of $235,234. These transactions were carried out under a pre-established 10b5-1 trading plan. Following these transactions, Ragosa holds 22,958 shares directly in the company. InvestingPro data shows the company maintains a strong financial position with more cash than debt on its balance sheet. Discover more insights about KNSA and access the comprehensive Pro Research Report, available for 1,400+ top US stocks, on InvestingPro.
In other recent news, Kiniksa Pharmaceuticals reported a significant 73% year-over-year growth in ARCALYST net product revenue in the third quarter of 2024, reaching $112.2 million. The company has also revised its full-year ARCALYST net sales guidance upwards to between $410 million and $420 million. Despite a net loss of $12.7 million for the quarter, Kiniksa's financial position is showing signs of improvement, with cash reserves reported at $223.8 million.
Kiniksa's initiatives for increasing disease awareness and expanding prescriber adoption have yielded encouraging results, with approximately 2,550 prescribers by the third quarter, a substantial number of whom are writing multiple prescriptions. The company's clinical pipeline, including ongoing trials for abiprubart in Sjögren's disease, remains a priority.
These are the latest developments for Kiniksa Pharmaceuticals, which continues to see strong ARCALYST sales growth and is focusing on expanding its prescriber base and disease awareness. The company's financial health, despite a quarterly net loss, appears to be strengthening with considerable cash reserves. It's worth noting that these facts are based on recent articles and may not reflect future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.